
WPD Pharmaceuticals sp. z o.o.
Research and experimental development on biotechnology
Overview
WPD Pharmaceuticals has no active business operations and holds shares in its former Polish subsidiary, WPD Pharmaceuticals Sp. z o.o. The Polish company is a biotechnology research and development company focused on oncology, including medicinal products involving biological compounds and small molecules. WPD Pharmaceuticals lost control of the Polish company in November 2022.
Financials
Revenue history (in k)
Financial insight
- The statement flags a going concern risk. Kapitał własny w bilansie spółki wykazuje wartość ujemną.
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 130 days for 2022). 1 of 5 audited by a statutory auditor.
- 2025filed
- 202413/07/2025
- 202312/07/2024
- 202222/11/2023
- 202103/10/2022
- 202011/11/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Websites
- wpdpharmaceuticals.comWPD Pharmaceuticals - HomeGoogle AnalyticsGoogle Tag ManagerApache
Public procurement
1 tender recorded as contractor, with a total value of $48,496.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Mar 18, 2025 | Production of recombinant protein WPD101a together with analysis of the interaction of protein WPD101a with the IL-13Ra2 receptor | $48,496$48,496 | Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu |
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 130,098 | $1,757,131.28 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-11-29.
76 1050 1070 1000 0090 8678 7927
11 1050 1298 1000 0090 8155 9271
78 1050 1298 1000 0090 3137 3369
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 21, 2022 | Call to creditors | |
| Feb 21, 2022 | Call to creditors |
Public aid
17 public aid cases recorded, with a total value of $22,342,028.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 5, 2025 | Aid for research and development projects: industrial research | $536.5K$536,451 | Prezes Agencji Badań Medycznych | |
| Apr 29, 2025 | Aid for research and development projects: industrial research | $550.6K$550,574 | Prezes Agencji Badań Medycznych | |
| Apr 29, 2025 | Aid for research and development projects: experimental development | $191.7K$191,688 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-01-01 | An innovative approach to the treatment of acute myeloid leukaemia (AML) | $5.3M$5,276,734 | Operational Programme Smart Growth | |
| 2019-01-01 | A new approach to glioma therapy addressing critical medical needs | $5.6M$5,604,432 | Operational Programme Smart Growth | |
| 2018-01-01 | Development of a new drug used to treat glioblastoma | $5.9M$5,922,532 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MAK Investments S.A. | $5,434,958.16 | mak-investments.pl | ||
| Ekipa Holding S.A. | $3,553,960.14 | ekipaholding.pl | ||
| 10X S.A. | $2,467,211.53 | 10xcapital.pl | ||
| KKV P.S.A. | $2,096,211.74 | kkv.com.pl | ||
| Duda Holding sp. z o.o. | $1,107,515.34 | dh.pl | ||
| Picasso sp. z o.o. | $1,101,232.46 | picasso.one | ||
| Vicis New Investments S.A. | $645,906.58 | vicis.pl | ||
| Grupa Coraz Lepsza Firma S.A. | $583,504.63 | grupaclf.pl | ||
| JNT Group S.A. | $441,353.62 | jntgroupsa.com | ||
| Mediacap Investments sp. z o.o. | $175,205.74 | mediacap.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-02-19 | Share capital increase (5,784,900.00 PLN → 6,504,900.00 PLN) | |
| 2023-12-11 | Share capital increase (5,108,700.00 PLN → 5,784,900.00 PLN) | |
| 2023-10-14 | Share capital increase (2,100,000.00 PLN → 5,108,700.00 PLN) | |
| 2022-11-25 | Share capital increase (400,000.00 PLN → 2,100,000.00 PLN) | |
| 2022-06-13 | Share capital reduction (2,969,200.00 PLN → 400,000.00 PLN) |
FAQ
Last updated: 2026-10-07